Assessing Durable Antibody Response to HPV Vaccination

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

October 23, 2024

Study Completion Date

May 31, 2026

Conditions
HPV
Interventions
BIOLOGICAL

Gardasil-9

"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."

DRUG

Lidocaine injections

"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."

Trial Locations (2)

30030

The Hope Clinic of Emory University, Atlanta

30322

Winship Cancer Institute, Atlanta

All Listed Sponsors
lead

Emory University

OTHER